The Cancer Exome Generated by Alternative mRNA Splicing Dilutes Predicted HLA Class I Epitope Density

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Stranzl, Thomas ^a   Larsen, Mette V ^a   Lund, Ole ^a   Nielsen, Morten ^a   Brunak, Søren ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; EXOME; EXPRESSED SEQUENCE TAG; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INTRON; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN MOTIF; RAT;

ALLELES; ALTERNATIVE SPLICING; AMINO ACID MOTIFS; DATABASES, GENETIC; EPITOPES; EXOME; GENE FREQUENCY; HLA ANTIGENS; HUMANS; NEOPLASMS; PEPTIDES; PROTEOME; RNA, MESSENGER;

EID: 84866713669     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038670     Document Type: Article

References (45)

1. Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, et al. (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Molecular & cellular proteomics: MCP 7: 1214-1224.
2. Skotheim RI, Nees M, (2007) Alternative splicing in cancer: noise, functional, or systematic? The international journal of biochemistry & cell biology 39: 1432-1449.
3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (New York, NY) 254: 1643-1647.
4. Finn OJ, (2008) Cancer immunology. The New England journal of medicine 358: 2704-2715.
5. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K, (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356: 1795-1799.
6. NA F, TA C, (2003) Pre-mRNA splicing and human disease. Genes Dev 17: 419-437.
7. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, et al. (2009) Cancer-associated regulation of alternative splicing. Nature structural & molecular biology 16: 670-676.
8. He C, Zuo Z, Chen H, Zhang L, Zhou F, et al. (2007) Genome-wide detection of testis- and testicular cancer-specific alternative splicing. Carcinogenesis 28: 2484-2490.
9. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, et al. (2006) Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC genomics 7: 325.
10. Ohnuma S, Miura K, Horii A, Fujibuchi W, Kaneko N, et al. (2009) Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues. Surgery 145: 57-68.
11. David CJ, Manley JL, (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes & development 24: 2343-2364.
12. Seliger B, (2008) Different regulation of MHC class I antigen processing components in human tumors. Journal of immunotoxicology 5: 361-367.
13. Romero JM, Jiménez P, Cabrera T, Cózar JM, Pedrinaci S, et al. (2005) Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International journal of cancer Journal international du cancer 113: 605-610.
14. Norell H, Carlsten M, Ohlum T, Malmberg K-J, Masucci G, et al. (2006) Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer research 66: 6387-6394.
15. Miranda NFCCD, Nielsen M, Pereira D, Puijenbroek MV, Vasen HF, et al. (2009) MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-de cient colorectal cancers. Journal of Pathology, The: 69-76. doi:10.1002/path.
16. Ferris RL, Whiteside TL, Ferrone S, (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 3890-3895.
17. Watson NFS, Ramage JM, Madjd Z, Spendlove I, Ellis IO, et al. (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. International journal of cancer Journal international du cancer 118: 6-10.
18. Ge B, Gurd S, Gaudin T, Dore C, Lepage P, et al. (2005) Survey of allelic expression using EST mining. Genome research 15: 1584-1591.
19. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2010) Database resources of the National Center for Biotechnology Information. Nucleic acids research 39: D38-D51.
20. Fang F, He X, Deng H, Chen Q, Lu J, et al. (2007) Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer science 98: 1678-1682.
21. Urayama S, Zou W, Brooks K, Tolstikov V, (2010) Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid communications in mass spectrometry: RCM 24: 613-620.
22. Figge M A, Blankenship L, (2004) Missense mutations in the BRCT domain of BRCA-1 from high-risk women frequently perturb strongly hydrophobic amino acids conserved among mammals. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 13: 1037-41.
23. Kauzmann W, (1959) Some factors in the interpretation of protein denaturation. Advances in protein chemistry 14: 1-63.
24. Figge MA, Blankenship L, (2004) Missense mutations in the BRCT domain of BRCA-1 from high-risk women frequently perturb strongly hydrophobic amino acids conserved among mammals. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 13: 1037-1041.
25. Wiedenfeld EA, Fernandez-Viña M, Berzofsky JA, Carbone DP, (1994) Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer research 54: 1175-7.
26. Koscielny G, Le Texier V, Gopalakrishnan C, Kumanduri V, Riethoven J-J, et al. (2009) ASTD: The Alternative Splicing and Transcript Diversity database. Genomics 93: 213-220.
27. Kelso J, Visagie J, Theiler G, Christoffels A, Bardien S, et al. (2003) eVOC: a controlled vocabulary for unifying gene expression data. Genome research 13: 1222-1230.
28. Wernersson R, (2006) Virtual Ribosome-a comprehensive DNA translation tool with support for integration of sequence feature annotation. Nucleic acids research 34: W385-W388.
29. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, et al. (2009) NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61: 1-13 Available: http://www.ncbi.nlm.nih.gov/pubmed/19002680.
30. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, et al. (2007) NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and-B Locus Protein of Known Sequence. PLoS ONE 2: e796.
31. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, et al. (2004) Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55: 797-810.
32. Zhang H, Lundegaard C, Nielsen M, (2009) Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods. Bioinformatics (Oxford, England) 25: 83-89.
33. Erup Larsen M, Kloverpris H, Stryhn A, Koofhethile CK, Sims S, et al. (2011) HLArestrictor - a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 63: 43-55.
34. Rao X, Costa AICAF, van Baarle D, Kesmir C, (2009) A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8+ T cell responses. Journal of immunology (Baltimore, Md: 1950) 182: 1526-1532.
35. Hopp TP, Woods KR, (1981) Prediction of protein antigenic determinants from amino acid sequences. Proceedings of the National Academy of Sciences of the United States of America 78: 3824-3828.
36. Wimley WC, White SH, (1996) Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nature structural biology 3: 842-848.
37. Simpson RJ (2002) Proteins and Proteomics: A Laboratory Manual. Cold Spring Harbor Laboratory Press. Available: http://www.amazon.com/Proteins-Proteomics-Laboratory-Richard-Simpson/dp/0879695544. Accessed 2011 Jul 18.
38. Trinquier G, Sanejouand YH, (1998) Which effective property of amino acids is best preserved by the genetic code? Protein engineering 11: 153-169.
39. Richards FM, (1977) Areas, volumes, packing and protein structure. Annual review of biophysics and bioengineering 6: 151-176.
40. Baumann G, Frömmel C, Sander C, (1989) Polarity as a criterion in protein design. Protein engineering 2: 329-334.
41. Darby NJ, Creighton TE (1993) Protein structure.
42. Miller S, Janin J, Lesk AM, Chothia C, (1987) Interior and surface of monomeric proteins. Journal of molecular biology 196: 641-656.
43. Nielsen M, Lundegaard C, Worning P, Hvid CS, Lamberth K, et al. (2004) Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics (Oxford, England) 20: 1388-1397.
44. Schneider TD, Stephens RM, (1990) Sequence logos: a new way to display consensus sequences. Nucleic acids research 18: 6097-6100.
45. Wilson E, (1927) Probable Inference, the Law of Succession, and Statistical Inference. Journal of the American Statistical Association 22: 209-212.